Accessibility Menu
 

Why GW Pharmaceuticals Dropped 14% in September

Lackluster trial results for its marijuana medicine for schizophrenia contributed to shares falling last month.

By Todd Campbell Updated Oct 8, 2015 at 7:40AM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.